tbuckley/cabot-search huggingface dataset:
Neonatology
Authors: Estelle B. Gauda
Journal: JAMA (1996)

Health care for newborns is under close scrutiny in this unsettling era of health system reform. Length of hospital stay for mothers and their newborns continues to shorten, antenatal corticosteroids improve outcome for premature infants and decrease overall costs, and survival of infants born at less than 25 weeks of gestation has improved, but morbidity is high, causing many to question the cost-effectiveness of advanced technologies. Ironically, early discharge after birth originally was demanded by women who wanted alternatives to a "standard" hospital delivery.<sup>1</sup>In 1980, the American Academy of Pediatrics (AAP) defined "early discharge" as a stay of 48 hours after an uncomplicated vaginal delivery and "very early discharge" as a stay of less than 24 hours. Eligibility guidelines were outlined as uncomplicated full-term pregnancy with good prenatal care, follow-up care arranged, and desire for early discharge. Subsequently, health insurers began to seek significant cost savings by refusing
Integration of a clinical pathways software into an EHR in a large, multisite, hospital affiliated community oncology setting.
Authors: Corey J. Shamah, Thomas James Saphner, Jacob C. Frick, Carol Huibregtse, Gail S. Stiemke
Journal: Journal of Clinical Oncology (2015)

e17555 Background: Via Oncology (Via) is a decision support tool that integrates patient information with a treatment algorithm. Via prioritizes treatments by efficacy first, toxicity second, and cost third. The recommended regimen is offered to the doctor and patient who may accept it or choose an off pathway treatment. The pathways are updated quarterly and are expected to speed the integration of new treatments into practice, standardize therapy, improve quality, and decrease cost. Physicians are often unaware that a trial is available for a patient and EHR’s (Electronic Health Record) are not commonly used to facilitate accrual to clinical trials. A pathway system could also alert doctors to the availability of a clinical trial and potentially increase accrual to clinical trials. Methods: The integration of Via into the Epic EHR was facilitated by 3 major interfaces: patient information sent from the EHR to Via, the providers’ schedules sent from the EHR to Via, and the protocol selected in Via sent back to the EHR. Within the decision algorithm, clinical trials were recommended as the first option in all lines of therapy when available. Results: After 3 months and 18,198 visits, the visit capture rate was 76.1%. With 1,590 decisions made, 91.6% of decisions were on pathway. Information about the number of trials recommended by the pathway and the number of times the recommendation was accepted is not available at this time. Information from our research department documented that 22 patients were accrued to clinical trials in the 79 days after Via implementation. Conclusions: The pathway program was rapidly accepted by physicians and the recommendations were commonly accepted. Information about trial accrual is not available is promising. An upgrade of the Epic EHR is planned in the near future. A single log in to open Via and the EHR concomitantly is planned. An additional interface to bring staging information from the EHR to Via is being planned. Quantification of the number of times a trial is offered and accepted is being captured.
Intracranial Surgery for Aneurysm: Effect of Hypothermia upon Survival
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NEW FOODS AND DRUGS LEGISLATION
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Preparation
Authors: Hugh F. Johnston
Journal: JAMA (1984)

My teachers in medical school were responsible people who realized that students often have difficulty dealing with the issues of death and dying. Thus, we had to read several papers and books on the subject and we all attended discussion groups. In these groups we talked a great deal about death. We discussed terminal illness, euthanasia, how we experienced death in our families, and even how we felt about our own eventual death. These groups met weekly for a whole semester, and when all of this scholarly work was done, we had a simple pass-fail essay examination. At the time it all seemed quite sensible and the course left us with that satisfying feeling of having reasonably mastered another subject. A year later, on the wards, I met Mr G. He was a typical veteran, a middle-aged bachelor with no known family. He had come in very short of breath
BLOOD EXAMINATION.
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Renal Disease
Authors: Andrew S. Levey
Journal: Annals of Internal Medicine (1998)

Letters15 April 1998Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Renal DiseaseAndrew S. Levey, MD, Joseph Lau, MD, and Ioannis Giatras, MDAndrew S. Levey, MDNew England Medical Center; Boston, MA 02111Search for more papers by this author, Joseph Lau, MDNew England Medical Center; Boston, MA 02111Search for more papers by this author, and Ioannis Giatras, MDNew England Medical Center; Boston, MA 02111Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-8-199804150-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We are pleased that Drs. Colindres and Kshirsagar acknowledge the methodologic strengths of our meta-analysis and the concordance of our findings with the large clinical trial reported by Maschio and colleagues. We agree that these factors make our findings more robust.Drs. Colindres and Kshirsagar also question our interpretation that “Angiotensin-converting enzyme inhibitors are more effective than other antihypertensive agents in reducing the development of end-stage nondiabetic renal disease” because 5 of the 10 studies compared ACE inhibitors with placebo rather than other antihypertensive agents. Table 3 of our article notes that studies using placebo in the control ... Author, Article, and Disclosure InformationAffiliations: New England Medical Center; Boston, MA 02111 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 April 1998Volume 128, Issue 8Page: 694-695KeywordsACE inhibitorsAngiotensin converting enzymeAngiotensin converting enzyme inhibitorAntihypertensive drug therapyBlood pressureClinical trial reportingRenal diseasesRenal failure ePublished: 15 August 2000 Issue Published: 15 April 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
THE COMPOSITION OF KOCH'S LYMPH.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pancreatic Cancer
Authors: R. M. Beazley, I. Cohn
Journal: CA A Cancer Journal for Clinicians (1981)

As a result of increased funding in the past few years, carcinoma of the pancreas has received increased investigative attention. A substantial body of epidemiologic data has been recorded, which may ultimately provide leads that identify an "at risk" population. Current diagnostic techniques enable clinicians to diagnose pancreatic lesions of relatively small size. Combined with further developments in the tumor marker field, it should be feasible to screen the at-risk population for early disease. Until then, only the early pancreatic lesion permits the slightest hope of cure.
Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine
Authors: G. Oster
Journal: JAMA (1987)

Using cholestyramine as a model, we considered the cost-effectiveness of antihyperlipemic therapy in the primary prevention of coronary heart disease among men between 35 and 74 years of age with elevated levels of total plasma cholesterol. Our findings indicate that the cost-effectiveness of treatment varies substantially, ranging from about $36 000 to over $1 million per year of life saved. Cost-effectiveness was highest for younger patients, for those with additional coronary risk factors (eg, smoking or hypertension), and for those whose course of therapy is of less-than-lifelong duration. Conversely, it is lowest for older patients, for those with no additional coronary risk factors, and for those who are treated for a lifetime. Our results suggest that pharmacologic therapy may not be cost-effective for all patients with elevated cholesterol levels, especially those over 65 years of age. For many younger patients, however—those with additional coronary risk factors and more severe elevations in cholesterol levels—the cost-effectiveness of therapy may be comparable with other accepted medical practices. (<i>JAMA</i>1987;258:2381-2387)
Erratum for Euro Surveill. 2017;22(1)
Journal: Eurosurveillance (2017)

© This work is licensed under a Creative Commons Attribution 4.0 International License. Closure This is a corrected article applying to the following content: Genetic characterisation of novel, highly pathogenic avian influenza (HPAI) H5N6 viruses isolated in birds, South Korea, November 2016
Eosinophilic gastroenteritis
Authors: R. H. Marshak
Journal: JAMA (1981)

THE CONCEPT of gastrointestinal allergy has not found a secure position in the literature. This diagnosis is usually considered when a patient with other allergic manifestations or history has otherwise unexplained gastrointestinal symptoms, usually associated with peripheral eosinophilia and an apparent intolerance to one or more foods. In such patients eosinophilic gastroenteritis may be encountered, a disease characterized by infiltration of the wall of the stomach, small bowel, or both, with eosinophils. Thirty years ago, Ingelfinger et al<sup>1</sup>offered criteria to be satisfied before incriminating a food as a cause of true gastrointestinal allergy, and in only a few cases have food substances been able to meet these standards of evidence. Leinbach and Rubin<sup>2</sup>have suggested that eosinophilic gastroenteritis is not a single reversible allergic reaction to specific foods but, rather, a chronic process that may be symptomatically aggravated by different foods. In some patients with eosinophilic gastroenteritis,
Patients with alcoholic hepatitis present strong Th1 cellular immune responses to alcohol dehydrogenase related to impairment of the PD-1/PD-L1 pathway due to high circulating levels of soluble PD-1
Authors: Laura Blackmore, Brandon Turner, Xiaohong Huang, Munther Hussain, Debbie L. Shawcross, Yun Ma
Journal: Journal of Hepatology (2020)
Birth season and schizophrenia.
Journal: BMJ (1978)

Birth season and schizophrenia "In the Spring a young man's fancy lightly turns to thoughts of love."'Whether for this biological reason or for some other, in many European countries the number of births is maximal in the first half-indeed, in the first quarter-of the year.In addition, in some of the Scandinavian countries, as Professor 0rnulf 0degArd has lately reminded us,2 there is a secondary sharp peak in September-obviously the consequence, he says, of festivities at Christmas and the New Year.In the southern hemisphere the birth peak remains in winter, and any possible secondary peak there in September caused by jollification at the turn of the year would be concealed.An association has been put forward between season of birth and an assortment of conditions, such as anencephaly,3 Down's syndrome,4 and twin births,5 but with few exceptions these suggestions so far remain tentative.The main exception is schizophrenia.Since interest first arose in the season of birth nearly all reliable large-scale studies have shown that more schizophrenic patients are born in the first four months of the year than would be expected; the excess is about 700 in the first quarter.The earlier investigators did not always avoid statis- tical man-traps, particularly in choosing control figures, but schizophrenia and January-April birth do seem to be associa- ted, at least in Norway,6 England and Wales,7 8 Denmark,9 Sweden,10 11 and perhaps elsewhere.In New South Wales there is an excess of winter-born among women with schizo- phrenia but not men.12What are we to make of this curious finding ?It has certainly already generated fresh theories about the causes of the disease.
RBP EIF2S2 Promotes Tumorigenesis and Progression by Regulating MYC-Mediated Inhibition via FHIT-Related Enhancers
Authors: Jiwei Zhang, Shengli Li, Ling Zhang, Juan Xu, Mingxu Song, Tingting Shao, Zhaohui Huang, Yongsheng Li
Journal: Molecular Therapy (2021)

(Mol Ther. 28, 1105–1118; April 8, 2020) In the originally published version of this article, Figure 2I has errors as a result of incorrect image files being used to compose the panel. The corrected Figure 2I now appears below. These corrections do not change the conclusions of the paper. The authors regret this error.Figure 2IEIF2S2 Increases GI Cancer Cell Proliferation, Invasion, and Metastasis In Vitro and In Vivo (Original)View Large Image Figure ViewerDownload Hi-res image Download (PPT) RBP EIF2S2 Promotes Tumorigenesis and Progression by Regulating MYC-Mediated Inhibition via FHIT-Related EnhancersZhang et al.Molecular TherapyFebruary 6, 2020In BriefRNA-binding proteins play important roles in cancer. Li et al. integrated multiple omics data that identified a potential oncogene, EIF2S2. Functional analyses provided detail knowledge of the function of the EIF2S2-LINC01600-MYC axis in gastrointestinal cancer, which will help the development of combination therapies for cancer. Full-Text PDF Open Archive
BUENOS AIRES
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction: Letters on Computed Tomography Screening for Lung Cancer
Journal: Clinical Cancer Research (2008)

Production of Letters to the Editor by Peter Bach, Gerard Silvestri, and Claudia Henschke, on the subject of computed tomography screening for lung cancer in the April 15 issue of Clinical Cancer Research, predated the AACR policy of publishing all authors' conflict of interest disclosures. In the interest of transparency, we are publishing disclosures originally provided to AACR by Drs. Bach and Silvestri and, more recently, by Dr. Henschke.Dr. Bach has disclosed no potential conflicts of interest.Dr. Silvestri has disclosed speaker's honoraria from Olympus, ownership interest in Alveolus, and consulting relationships with Olympus and Alveolus.Dr. Henschke has the following relationship with General Electric and the National Cancer Institute (NCI):Dr. Henschke also receives research support in the form of grants and contracts from: American Legacy Foundation, Flight Attendants' Medical Research Institute, NCI, AstraZeneca, Inc., Carestream Health, Inc., and the Foundation for Lung Cancer: early detection, prevention and treatment (primary source of funding was an unrestricted gift by the Vector group, the parent company of Liggett Tobacco).The following is a listing of the patent and patent applications in which Claudia Henschke is listed as a co-inventor.Bach P: Computed tomography screening for lung cancer (letter). Clin Cancer Res 2008;14:2511.Silvestri G: Deaths among patients with screen-detected lung cancer (letter). Clin Cancer Res 2008;14:2511.Henschke C: In response (letter). Clin Cancer Res 2008;14:2511–2.
The effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: Secondary analysis of RTOG 98-02.
Authors: Roshan Sudhir Prabhu, Minhee Won, Edward G. Shaw, Meihua Wang, David Brachman, Minesh P. Mehta
Journal: Journal of Clinical Oncology (2012)

2047 Background: The addition of PCV chemotherapy to radiotherapy (RT) for patients with WHO grade II glioma improves progression free survival (PFS) and overall survival (OS), for patients surviving at least 2 years (Shaw, J Clin Oncol 26: 2008). The effect of therapy intensification on cognitive function (CF) remains a concern in this population with substantial long term survival. Methods: 251patients with WHO grade II glioma and age &gt; 40 with any extent of resection, or age &lt; 40 with subtotal resection/biopsy were randomized to RT (54Gy) or RT + PCV. 111 patients with age &lt; 40 and gross total resection were observed. CF was assessed by mini-mental status exam (MMSE)at baseline and years 1, 3, and 5 for patients without progression. Change in MMSE score from baseline of &gt; 3 points was considered clinically significant. Results: Overall, very few patients experienced significant decline in MMSE score, with a median follow-up time of 9.7 years for alive patients. There were no significant differences in the proportion of patients experiencing MMSE decline between study arms at any time point. The table below summarizes MMSE change from baseline over time. Neither baseline MMSE score nor change in MMSE at year 1 significantly predicted for OS or PFS, but there was a trend towards worse OS for patients with MMSE loss of ≥ 2 points [HR 1.73, 95% CI (0.86, 3.47), p=0.12]. Conclusions: The MMSE is a relatively insensitive tool that has not been validated in patients receiving cranial RT, and subtle changes in CF may have been missed. However, the addition of PCV to RT for low grade glioma did not result in significantly higher rates of MMSE decline than RT alone or observation. There was a trend towards an MMSE decline of ≥ 2 points at year 1 predicting for worse OS. [Table: see text]
Modelling liver tumor organoids and cancer-associated fibroblasts interaction reveals the robust effects of stromal niche in cancer nurturing and treatment resistance
Authors: Jiaye Liu, Pengfei Li, Ling Wang, Meng Li, Zhouhong Ge, Lisanne Noordam, Ruby Lieshout, Monique M.A. Verstegen, Buyun Ma, Junhong Su, Dave Sprengers, Ruyi Zhang, Guoying Zhou, Ron Smits, Jaap Kwekkeboom, Luc J.W. van der Laan, Maikel Peppelenbosch, Qiuwei Pan, Wanlu Cao
Journal: Journal of Hepatology (2020)